ArticleCancer biology & therapy2017
miR-337 can be a key negative regulator in melanoma.
Article in Cancer biology & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- MiR-337-3p improves metabolic-associated fatty liver disease through regulation of glycolipid metabolism.iScience · 2023Article
- MicroRNA Alterations Induced in Human Skin by Diesel Fumes, Ozone, and UV Radiation.Journal of personalized medicine · 2022Article
- MicroRNA Signature in Melanoma: Biomarkers and Therapeutic Targets.Frontiers in oncology · 2021Review
- Down-regulated HDAC3 elevates microRNA-495-3p to restrain epithelial-mesenchymal transition and oncogenicity of melanoma cells via reducing TRAF5.Journal of cellular and molecular medicine · 2020Article
- miR-337 suppresses cutaneous T-cell lymphoma via the STAT3 pathway.Cell cycle (Georgetown, Tex.) · 2019Article
- MicroRNA-337 regulates the PI3K/AKT and Wnt/β-catenin signaling pathways to inhibit hepatocellular carcinoma progression by targeting high-mobility group AT-hook 2.American journal of cancer research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Incidence of melanoma is increasing annually worldwide. There remains a lack of suitable treatment methods which can significantly improve the 5-year survival rates of patients. It is established that micro RNAs (miRNAs) have important roles in the diagnosis and treatment of cancer. MiR-337 had been reported to regulate the development of variety of cancers, as a cancer suppressive factor. In our research we found that miR-337 had a lower expression in melanoma than adjacent tissues. The patients who had a lower miR-337 also got a worse survival. MiR-337 could target STAT3 to regulate the occurrence and development of melanoma. In summary, our findings suggest that the miR-337/STAT3 axis may serve as a potential target for the treatment of melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.